Despite Attractive End Markets, Analyst Outlines Concerns For Repligen Stock
RBC Capital Markets has initiated coverage on Repligen Corporation (NASDAQ: RGEN) with a Sector Perform rating and a price target of $190.
The analyst likes the company due to product differentiation in some of the fastest-growing areas of biopharma.
But RBC is hesitant towards the stock due to the 12.7x sales multiple, lack of operational earnings beats, declining gross margins, and low absolute R&D investment relative to larger companies in the space.
Related: Repligen Beefs Up Process Analytics Portfolio With DRS Daylight Solutions Pact.
Repligen is a pure play in the biopharma production sector, which has exploded over the last 2-3 years and remains the fastest-growing market in life sciences, tools & diagnostics, with first-mover advantage in many product areas.
But the larger players have taken notice – with M&A and capacity expansion investments, thus concerning the analyst about future growth prospects in what could become a very crowded market.
Price Action: RGEN shares are up 1.47% at $171.61 on the last check Wednesday.
Photo Via Company
Latest Ratings for RGEN
Date | Firm | Action | From | To |
|---|---|---|---|---|
Feb 2022 | SVB Leerink | Maintains | Outperform | |
Oct 2021 | SVB Leerink | Maintains | Outperform | |
Oct 2021 | Exane BNP Paribas | Initiates Coverage On | Outperform |
View More Analyst Ratings for RGEN
View the Latest Analyst Ratings
See more from Benzinga
GSK's Jemperli/Chemo Combo Shows Response Rate Of 46% In Head-To-Head Lung Cancer Trial
Eli Lilly's Diabetes Drug Shows Statistical Reduction In Blood Sugar Levels In Children, Adolescents
Trump's Billionaire Neighbor Warned The Economy Was In An 'Omnibubble,' He Was Right
Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
